Ambrisentan
- Generic Name
- Ambrisentan
- Brand Names
- Letairis, Volibris, Ambrisentan Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C22H22N2O4
- CAS Number
- 177036-94-1
- Unique Ingredient Identifier
- HW6NV07QEC
- Background
Ambrisentan is an orally active selective type A endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. It is approved in Europe, Canada and the United States for use as a single agent to improve exercise ability and delay clinical worsening. In addition, it is approved in the United States for use in combination with tadalafil to reduce the risks of disease progression, hospitalization and to improve exercise ability. Studies establishing the efficacy of Ambrisentan included patients with both idiopathic or heritable pulmonary arterial hypertension and those with pulmonary arterial hypertension associated with connective tissue diseases. Patients studied displayed symptoms and etiologies predominantly of WHO Functional Class II-III. As an endothelin receptor antagonist, Ambrisentan prevents endogenous endothelin peptide from constricting the muscles in blood vessels, allowing them to relax and permit a reduction in blood pressure.
- Indication
用于治疗肺动脉高血压(PAH)。
- Associated Conditions
- Pulmonary arterial hypertension WHO functional class I
Endothelin Receptor Antagonism with Ambrisentan to Treat Hepatorenal Syndrome
- Conditions
- Acute Kidney InjuryHepatorenal SyndromeLiver CirrhosisAscites Hepatic
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Noorik Biopharmaceuticals AG
- Target Recruit Count
- 54
- Registration Number
- NCT06256432
- Locations
- 🇮🇳
Asian Institute of Gastroenterology (AIG), Hyderabad, Telangana, India
🇮🇳All India Institute of Medical Sciences, New Delhi, Delhi, India
🇮🇳Aster CMI Hospital, Bangalore, Karnataka, India
Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation
- Conditions
- Type 1 Diabetes Mellitus With Diabetic Nephropathy
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 36
- Registration Number
- NCT06072326
- Locations
- 🇨🇦
University of Toronto, Toronto, Canada
🇫🇮University of Helsinki, Helsinki, Uusimaa, Finland
🇳🇱Amsterdam University Academic Center, Amsterdam, Noord Holland, Netherlands
Efficacy and Safety Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2022-06-29
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT05437224
- Locations
- 🇨🇳
Renji Hospital, Shanghai, China
Treatment With Ambrisentan in Patients With Borderline Pulmonary Arterial Hypertension
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2022-09-28
- Target Recruit Count
- 420
- Registration Number
- NCT04972656
- Locations
- 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China
A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Noorik Biopharmaceuticals AG
- Target Recruit Count
- 88
- Registration Number
- NCT04771000
- Locations
- 🇪🇸
University Hospital 12 de Octubre, Madrid, Spain
🇪🇸Hospital Universitario San Cecilio, Granada, Comunidad De Andalucia, Spain
🇪🇸Hospital Universitario Infanta Leonor, Madrid, Spain
Pilot Study of the Safety and Efficacy of Sulfasalazine in Pulmonary Arterial Hypertension
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT04528056
- Locations
- 🇨🇳
Renji Hospital, Shanghai, China
Effects of Endothelin Receptor Antagonist on Ischemic Kidney Injury During Nephron Sparing Surgery
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Bnai Zion Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT04450095
- Locations
- 🇮🇱
Bnai-Zion Medical Center, Haifa, Israel
🇮🇱Department of Physiology, The Bruce and Ruth Rapapport Faculty of Medicine, Technion, Haifa, Israel
mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2023-07-28
- Target Recruit Count
- 454
- Registration Number
- NCT04393246
- Locations
- 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Noorik Biopharmaceuticals AG
- Target Recruit Count
- 19
- Registration Number
- NCT03827200
- Locations
- 🇪🇸
Hospital Clinic Barcelona, Barcelona, Catalunya, Spain
🇪🇸Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain
🇪🇸Vall d'Hebron University Hospital, Barcelona, Spain
Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension
- Conditions
- Portopulmonary HypertensionPulmonary HypertensionCirrhosis, Liver
- Interventions
- First Posted Date
- 2017-10-13
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Ochsner Health System
- Registration Number
- NCT03309592
- Locations
- 🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.